Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


Articles published in Ann Hematol

Retrieve available abstracts of 349 articles:
HTML format



Single Articles


    April 2024
  1. LIU S, Cui Q, Li M, Li Z, et al
    Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
    Ann Hematol. 2024;103:1397-1402.
    PubMed     Abstract available


  2. REN Y, Liu F, Chen X, Zhang X, et al
    Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:1345-1351.
    PubMed     Abstract available


  3. LUCERO J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, et al
    Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2024;103:1187-1196.
    PubMed     Abstract available


    March 2024
  4. KUROSAWA S, Yokota T, Takada Y, Okubo S, et al
    Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.
    Ann Hematol. 2024 Mar 21. doi: 10.1007/s00277-024-05721.
    PubMed    


  5. HUANG XT, Wang CJ, Gao C, Xue TL, et al
    Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.
    Ann Hematol. 2024 Mar 18. doi: 10.1007/s00277-024-05687.
    PubMed     Abstract available


  6. OU J, Deng S, Ding C, Cai Z, et al
    Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia.
    Ann Hematol. 2024 Mar 7. doi: 10.1007/s00277-024-05681.
    PubMed     Abstract available


  7. RORVIK SD, Torkildsen S, Bruserud O, Tvedt THA, et al
    Acute myeloid leukemia with rare recurring translocations-an overview of the entities included in the international consensus classification.
    Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05680.
    PubMed     Abstract available


  8. DARTIGEAS C, Quinquenel A, Ysebaert L, Dilhuydy MS, et al
    Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
    Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05666.
    PubMed     Abstract available


  9. WU X, Ma X, Song T, Liu J, et al
    The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping.
    Ann Hematol. 2024;103:917-933.
    PubMed     Abstract available


  10. KENNEDY A, Patel S, Ramanathan M, Gerber J, et al
    Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.
    Ann Hematol. 2024;103:1031-1033.
    PubMed    


  11. KRECAK I, Cubric E, Smolic J, Vrbicic B, et al
    Small lymphocytic lymphoma infiltrating gastrointestinal tract and mimicking inflammatory bowel disease, successfully treated with acalabrutinib.
    Ann Hematol. 2024;103:1021-1023.
    PubMed    


  12. PALANI HK, Ganesan S, Balasundaram N, Venkatraman A, et al
    Cystatin F a potential diagnostic biomarker in acute promyelocytic leukemia.
    Ann Hematol. 2024 Mar 1. doi: 10.1007/s00277-024-05673.
    PubMed    


    February 2024
  13. SCHWANER I, Kuhn T, Losem C, Wolff T, et al
    Low incidence of tumor lysis syndrome in elderly patients with chronic lymphocytic leukemia treated with venetoclax under real-world conditions: results from the prospective observational VeRVe study.
    Ann Hematol. 2024 Feb 29. doi: 10.1007/s00277-024-05638.
    PubMed     Abstract available


  14. CHEN Y, Zheng J, Weng Y, Wu Z, et al
    Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.
    Ann Hematol. 2024 Feb 27. doi: 10.1007/s00277-024-05679.
    PubMed     Abstract available


  15. TERAMOTO M, Tamaki H, Kaida K, Samori M, et al
    Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis.
    Ann Hematol. 2024 Feb 23. doi: 10.1007/s00277-024-05654.
    PubMed     Abstract available


  16. WANG X, Zhang Y, Xue S
    Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
    Ann Hematol. 2024 Feb 21. doi: 10.1007/s00277-023-05601.
    PubMed     Abstract available


  17. GOTO T, Nakamura N, Suzaki T, Shimazu R, et al
    A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration.
    Ann Hematol. 2024 Feb 20. doi: 10.1007/s00277-024-05660.
    PubMed    


  18. LI X, Zhou J, Li J, Zhu X, et al
    Effectiveness and safety of blinatumomab for pediatric B cell acute lymphoblastic leukemia with Loeffler's endocarditis.
    Ann Hematol. 2024 Feb 17. doi: 10.1007/s00277-024-05656.
    PubMed    


  19. ZHAO L, Yang J, Chen M, Xiang X, et al
    Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
    Ann Hematol. 2024 Feb 8. doi: 10.1007/s00277-024-05646.
    PubMed     Abstract available


  20. FONTANA D, Zambrotta GPM, Scannella A, Piazza R, et al
    Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.
    Ann Hematol. 2024 Feb 7. doi: 10.1007/s00277-024-05649.
    PubMed     Abstract available


  21. SCHLOSSER P, Schiwitza A, Klaus J, Hieke-Schulz S, et al
    Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia.
    Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05627.
    PubMed     Abstract available


  22. SUAREZ EU, Piris MA, Rodriguez-Pinilla SM, Garcia JF, et al
    Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage.
    Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05647.
    PubMed    


  23. WANG J, Zhang H, Zhang R
    BRCA2 germline mutation in familial leukaemia with familial breast cancer: a case report.
    Ann Hematol. 2024;103:685-687.
    PubMed    


  24. BRUNNER A, Thalhammer-Thurner GC, Willenbacher W, Haun M, et al
    In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation.
    Ann Hematol. 2024;103:553-563.
    PubMed     Abstract available


  25. FERNANDEZ-LUIS S, Gomez Lamas D, Cerezo Martin JM, Mora Barrios JM, et al
    Feasibility of allogeneic hematopoietic stem cell transplantation in advanced age.
    Ann Hematol. 2024;103:583-591.
    PubMed     Abstract available


    January 2024
  26. CHEN Y, Pan M, Chen L, Peng M, et al
    Identification of a novel fusion gene, RARA::ANKRD34C, in acute promyelocytic leukemia.
    Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05629.
    PubMed     Abstract available


  27. CUI J, Zhao M, Liu W, Hong M, et al
    Effect of low skeletal muscle mass on NK cells in patients with acute myeloid leukemia and its correlation with prognosis.
    Ann Hematol. 2024 Jan 31. doi: 10.1007/s00277-024-05645.
    PubMed     Abstract available


  28. LIU Y, Ma Z
    Leukemia and mitophagy: a novel perspective for understanding oncogenesis and resistance.
    Ann Hematol. 2024 Jan 29. doi: 10.1007/s00277-024-05635.
    PubMed     Abstract available


  29. GABELLIER L, Peterlin P, Thepot S, Hicheri Y, et al
    Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
    Ann Hematol. 2024 Jan 26. doi: 10.1007/s00277-024-05623.
    PubMed     Abstract available


  30. CHATTOPADHYAY S, Lionel S, Selvarajan S, Devasia AJ, et al
    Relapse and transformation to myelodysplastic syndrome and acute myeloid leukemia following immunosuppressive therapy for aplastic anemia is more common as compared to allogeneic stem cell transplantation with a negative impact on survival.
    Ann Hematol. 2024 Jan 20. doi: 10.1007/s00277-024-05621.
    PubMed     Abstract available


  31. MURRU R, Galitzia A, Barabino L, Presicci R, et al
    Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis.
    Ann Hematol. 2024 Jan 18. doi: 10.1007/s00277-024-05625.
    PubMed     Abstract available


  32. ZHAO Y, Zhang X, Zhang M, Guo R, et al
    Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy.
    Ann Hematol. 2024 Jan 12. doi: 10.1007/s00277-024-05617.
    PubMed     Abstract available


  33. DEREME J, Voruz S, Solly F, Schoumans J, et al
    Philadelphia chromosome-positive B cell acute lymphoblastic phase arising 24 years after treatment-free remission for chronic myeloid leukemia with identical BCR-ABL fusion transcript.
    Ann Hematol. 2024 Jan 9. doi: 10.1007/s00277-023-05600.
    PubMed    


  34. SONG J, Li W, Bai Y, Zhou P, et al
    A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
    Ann Hematol. 2024 Jan 6. doi: 10.1007/s00277-023-05594.
    PubMed     Abstract available


  35. PERRUSO LL, Velloso E, Rocha V, Rego EM, et al
    Patterns and prognostic impact of CNS infiltration in adults with newly diagnosed acute lymphoblastic leukemia.
    Ann Hematol. 2024 Jan 5. doi: 10.1007/s00277-023-05609.
    PubMed     Abstract available


  36. WANG R, Xu Y, Wang B, Wang H, et al
    Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
    Ann Hematol. 2024;103:61-71.
    PubMed     Abstract available


  37. AL BARASHDI MAS, Ali A, McMullin MF, Mills K, et al
    CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy.
    Ann Hematol. 2024;103:73-88.
    PubMed     Abstract available


    December 2023
  38. HUANG P, Chang H, Zhang R, Wu Y, et al
    Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia.
    Ann Hematol. 2023 Dec 28. doi: 10.1007/s00277-023-05593.
    PubMed     Abstract available


  39. PAN B, Xu Z, Du K, Gao R, et al
    Investigation of fatty acid metabolism in chronic lymphocytic leukemia to guide clinical outcome and therapy.
    Ann Hematol. 2023 Dec 27. doi: 10.1007/s00277-023-05590.
    PubMed     Abstract available


  40. SOBAS M, Knopinska-Posluszny W, Piatkowska-Jakubas B, Garcia-Alvarez F, et al
    Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
    Ann Hematol. 2023 Dec 19. doi: 10.1007/s00277-023-05582.
    PubMed     Abstract available


  41. PARK T, Byun JM, Shin DY, Koh Y, et al
    Clinical characteristics and treatment outcomes of Asian patients with T-cell large granular lymphocytic Leukemia: a single-center analysis of 67 cases.
    Ann Hematol. 2023 Dec 8. doi: 10.1007/s00277-023-05575.
    PubMed     Abstract available


  42. ZHENG X, Gao H, Lu N, Wang M, et al
    Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
    Ann Hematol. 2023;102:3603-3611.
    PubMed     Abstract available


  43. HU J, Zhao J, Wang C, Jia M, et al
    Epstein-Barr virus reactivation correlates with worse outcomes for patients exposed to hepatitis B virus after haploidentical hematopoietic stem cell transplantation.
    Ann Hematol. 2023;102:3593-3601.
    PubMed     Abstract available


  44. ANDERSEN M JR, Bindal P, Michaels P, Elavalakanar P, et al
    Clonal myeloid disorders following CAR T-cell therapy.
    Ann Hematol. 2023;102:3643-3645.
    PubMed    


  45. BEWERSDORF JP, Shallis RM, Sharon E, Park S, et al
    A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
    Ann Hematol. 2023 Dec 1. doi: 10.1007/s00277-023-05552.
    PubMed     Abstract available


    November 2023
  46. MARRA JD, Frioni F, Minnella G, Rossi M, et al
    Acute erythroid leukemia with TP53 mutation and BCR/ABL1: challenges in classification and management.
    Ann Hematol. 2023 Nov 29. doi: 10.1007/s00277-023-05561.
    PubMed    


  47. MULAS O, Abruzzese E, Luciano L, Iurlo A, et al
    The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
    Ann Hematol. 2023 Nov 28. doi: 10.1007/s00277-023-05556.
    PubMed     Abstract available


  48. ISHIDA H, Arakawa Y, Hasegawa D, Usami I, et al
    Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 25. doi: 10.1007/s00277-023-05557.
    PubMed     Abstract available


  49. FISCHER D, Toenges R, Kiil K, Michalik S, et al
    Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 24. doi: 10.1007/s00277-023-05495.
    PubMed     Abstract available


  50. SHANG CY, Bei LY, Wu JZ, Sheng HR, et al
    NOTCH pathway mutation contributes to inferior prognosis in HBV-infected chronic lymphocytic leukemia.
    Ann Hematol. 2023 Nov 23. doi: 10.1007/s00277-023-05554.
    PubMed     Abstract available


  51. GAO J, Han S, Deng B, Deng Y, et al
    Research progress of additional pathogenic mutations in chronic neutrophilic leukemia.
    Ann Hematol. 2023 Nov 22. doi: 10.1007/s00277-023-05550.
    PubMed     Abstract available


  52. TIAN J, Wei A, Wang B, Yang J, et al
    Allogeneic hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 22. doi: 10.1007/s00277-023-05506.
    PubMed     Abstract available


  53. LAP CJ, Abrahim MS, Nassereddine S
    Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia.
    Ann Hematol. 2023 Nov 17. doi: 10.1007/s00277-023-05545.
    PubMed     Abstract available


  54. CHEN B, Zhao Y, Xu S, Jiang F, et al
    USF2 promotes autophagy and proliferation in chronic lymphocytic leukemia by inhibiting STUB1-induced NFAT5 ubiquitination.
    Ann Hematol. 2023 Nov 10. doi: 10.1007/s00277-023-05522.
    PubMed     Abstract available


  55. LUCIJANIC M, Tomasovic-Loncaric C, Stoos-Veic T, De Both T, et al
    Myeloid sarcoma of the urinary bladder as the presenting feature of secondary acute myeloid leukemia, successfully treated with venetoclax and azacitidine.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05529.
    PubMed    


  56. AHMED HA, Nafady A, Ahmed EH, Hassan EEN, et al
    CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05540.
    PubMed     Abstract available


  57. FAN S, Wang L, Lu Y, Li Z, et al
    Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05519.
    PubMed     Abstract available


  58. DE OLIVEIRA FERNANDES JUNIOR I, Arcuri LJ
    Myeloablative or reduced-intensity/non-myeloablative hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in adults older than 40 years old - a secondary analysis of a CIBMTR database.
    Ann Hematol. 2023 Nov 9. doi: 10.1007/s00277-023-05532.
    PubMed     Abstract available


  59. BABAKHANLOU R, Nader ME, Alvarado Y
    Correction to: A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia.
    Ann Hematol. 2023 Nov 3. doi: 10.1007/s00277-023-05524.
    PubMed    


  60. HUSSAN SS, Ali MS, Fatima M, Altaf M, et al
    Epigenetically dysregulated NOTCH-Delta-HES signaling cascade can serve as a subtype classifier for acute lymphoblastic leukemia.
    Ann Hematol. 2023 Nov 3. doi: 10.1007/s00277-023-05515.
    PubMed     Abstract available


  61. HUANG X, Li T, Zhang Y, Gao X, et al
    Hemophagocytosis by multinucleated leukemic blasts, basophilia, and micromegakaryocytes in AML with TLS::ERG.
    Ann Hematol. 2023;102:3279-3281.
    PubMed    


    October 2023
  62. SAVANI S, Chennapragada SS, Ramphul K, Dandwani M, et al
    Factors associated with inpatient mortality during daunorubicin and cytarabine induction in adults with acute myeloid leukemia-a national inpatient sample analysis.
    Ann Hematol. 2023 Oct 27. doi: 10.1007/s00277-023-05505.
    PubMed    


  63. TANG H, Chen Y, Zhang N, Deng J, et al
    Higher expression of programmed cell death 4 (PDCD4) in acute myeloid leukemia is associated with better prognosis after chemotherapy.
    Ann Hematol. 2023 Oct 25. doi: 10.1007/s00277-023-05516.
    PubMed     Abstract available


  64. CUI Y, Peng H
    Imatinib and CAR T cell therapy enable sustained response in a young patient with refractory RCSD1-ABL1-positive acute lymphoblastic leukemia.
    Ann Hematol. 2023 Oct 21. doi: 10.1007/s00277-023-05489.
    PubMed    


  65. FEI X, Zhang W, Gu J, Yang F, et al
    CLAG combined with total body irradiation as intensive conditioning chemotherapy prior to allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.
    Ann Hematol. 2023 Oct 17. doi: 10.1007/s00277-023-05502.
    PubMed     Abstract available


  66. YIN S, Zheng X, Zhang W, Zhao H, et al
    Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis.
    Ann Hematol. 2023 Oct 16. doi: 10.1007/s00277-023-05486.
    PubMed     Abstract available


  67. EISENACH S, Zinke J, Bramer D, Hartinger S, et al
    Detection of a rare JAK2(exon13InDel)-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Loffler endocarditis.
    Ann Hematol. 2023 Oct 16. doi: 10.1007/s00277-023-05490.
    PubMed    


  68. CREMER A, Enssle JC, Pfaff S, Kouidri K, et al
    Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML.
    Ann Hematol. 2023;102:2903-2908.
    PubMed     Abstract available


  69. MARTINO G, Cimino G, Caridi M, Perta G, et al
    One disease, two faces: clonally-related AML and MPDCP with skin involvement.
    Ann Hematol. 2023;102:2969-2971.
    PubMed    


    September 2023
  70. XU Y, Gao H, Li H
    The gut microbiome: an important factor influencing therapy for pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2023 Sep 29. doi: 10.1007/s00277-023-05480.
    PubMed     Abstract available


  71. PEREIRA MP, Herrity E, Kim DDH
    TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
    Ann Hematol. 2023 Sep 28. doi: 10.1007/s00277-023-05462.
    PubMed     Abstract available


  72. ZOU D, Lv M, Chen Y, Niu T, et al
    Down-regulation of Musashi-2 exerts antileukemic effects on acute lymphoblastic leukemia cells and increases sensitivity to dexamethasone.
    Ann Hematol. 2023 Sep 26. doi: 10.1007/s00277-023-05468.
    PubMed     Abstract available


  73. CANDAN O, Demirtas D, Yanik AM, Atagunduz I, et al
    The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia.
    Ann Hematol. 2023 Sep 20. doi: 10.1007/s00277-023-05456.
    PubMed    


  74. LIN Q, Ye P, Wang T, Lu Y, et al
    Successful use of venetoclax combined with azacitidine in isolated extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report.
    Ann Hematol. 2023 Sep 20. doi: 10.1007/s00277-023-05401.
    PubMed    


  75. LI H, Hou J, Fu Y, Zhao Y, et al
    miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia.
    Ann Hematol. 2023 Sep 19. doi: 10.1007/s00277-023-05441.
    PubMed     Abstract available


  76. WENG G, Huang J, He X, Xue T, et al
    Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
    Ann Hematol. 2023 Sep 18. doi: 10.1007/s00277-023-05452.
    PubMed     Abstract available


  77. BABAKHANLOU R, Ellie-Nader M, Alvarado Y
    A case of sudden hearing loss in a patient with chronic myelomonocytic leukemia.
    Ann Hematol. 2023 Sep 15. doi: 10.1007/s00277-023-05433.
    PubMed     Abstract available


  78. CROUCHER PJP, Ridinger M, Becker PS, Lin TL, et al
    Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
    Ann Hematol. 2023 Sep 13. doi: 10.1007/s00277-023-05442.
    PubMed     Abstract available


  79. JIANG S, Lu X, Wei R, Zhang A, et al
    Salvage hematopoietic stem cell transplantation for patients with higher leukemia burden in relapsed or refractory acute myeloid leukemia: a ten-year study.
    Ann Hematol. 2023 Sep 8. doi: 10.1007/s00277-023-05406.
    PubMed     Abstract available


  80. WANG Q, Liang Z, Ren H, Dong Y, et al
    Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2023 Sep 4. doi: 10.1007/s00277-023-05429.
    PubMed     Abstract available


  81. LIU Y, Chen P, Chen G, Chen X, et al
    E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
    Ann Hematol. 2023 Sep 4. doi: 10.1007/s00277-023-05431.
    PubMed     Abstract available


  82. WANG S, Wang X, Shen K, Wei C, et al
    Insulin-like growth factor 1 receptor inhibits the proliferation of acute myeloid leukaemia cells via NK cell activation.
    Ann Hematol. 2023;102:2353-2364.
    PubMed     Abstract available


  83. LI VWK, Yim R, Lee P, Chin L, et al
    Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction.
    Ann Hematol. 2023;102:2517-2527.
    PubMed     Abstract available


    August 2023
  84. INFANTE J, Esteves G, Raposo J, de Lacerda JF, et al
    Predictors of very early death in acute promyelocytic leukemia: a retrospective real-world cohort study.
    Ann Hematol. 2023 Aug 31. doi: 10.1007/s00277-023-05422.
    PubMed     Abstract available


  85. KIMURA H, Onozawa M, Yoshida S, Miyashita N, et al
    Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
    Ann Hematol. 2023 Aug 19. doi: 10.1007/s00277-023-05405.
    PubMed     Abstract available


  86. ISFORT S, Manz K, Teichmann LL, Crysandt M, et al
    Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study.
    Ann Hematol. 2023 Aug 18. doi: 10.1007/s00277-023-05394.
    PubMed     Abstract available


  87. CORBINGI A, Putzulu R, Massini G, Colangelo M, et al
    Genetic mutations and leukapheresis in acute myeloid leukemia: is there a link?
    Ann Hematol. 2023 Aug 17. doi: 10.1007/s00277-023-05414.
    PubMed     Abstract available


  88. QI F, Bao M, Gao H, Zhang X, et al
    Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.
    Ann Hematol. 2023 Aug 14. doi: 10.1007/s00277-023-05413.
    PubMed     Abstract available


  89. DUAN W, Yang S, Zhao T, Hu L, et al
    Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
    Ann Hematol. 2023 Aug 12. doi: 10.1007/s00277-023-05400.
    PubMed     Abstract available


  90. BORAH P, Dayal N, Pathak S, Naithani R, et al
    Daratumumab-a novel treatment strategy in relapsed/refractory acute leukemia.
    Ann Hematol. 2023 Aug 9. doi: 10.1007/s00277-023-05404.
    PubMed    


  91. LIU K, Shao J, Cai J, Tang J, et al
    Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children's Cancer Group study ALL-2015.
    Ann Hematol. 2023 Aug 8. doi: 10.1007/s00277-023-05389.
    PubMed     Abstract available


  92. FRACCAROLI A, Vogt D, Rothmayer M, Spiekermann K, et al
    Impact of extramedullary disease in AML patients undergoing sequential RIC for HLA-matched transplantation: occurrence, risk factors, relapse patterns, and outcome.
    Ann Hematol. 2023;102:2213-2223.
    PubMed     Abstract available


  93. LOSCOCCO GG, Vannucchi AM
    Myeloid sarcoma: more and less than a distinct entity.
    Ann Hematol. 2023;102:1973-1984.
    PubMed     Abstract available


  94. LUBKE J, Naumann N, Metzgeroth G, Kreil S, et al
    Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis.
    Ann Hematol. 2023;102:2077-2085.
    PubMed     Abstract available


  95. RAHMATI A, Mafi A, Vakili O, Soleymani F, et al
    Non-coding RNAs in leukemia drug resistance: new perspectives on molecular mechanisms and signaling pathways.
    Ann Hematol. 2023 Aug 1. doi: 10.1007/s00277-023-05383.
    PubMed     Abstract available


    July 2023
  96. GAO J, Gao J, Min F
    Chronic neutrophilic leukemia with JAK2 mutation: is it true chronic neutrophilic leukemia?
    Ann Hematol. 2023 Jul 31. doi: 10.1007/s00277-023-05376.
    PubMed    


  97. STADLER M, Hambach L, Dammann E, Diedrich H, et al
    The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease.
    Ann Hematol. 2023 Jul 25. doi: 10.1007/s00277-023-05276.
    PubMed     Abstract available


  98. ARAIE H, Arai Y, Kida M, Aoki J, et al
    Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapy.
    Ann Hematol. 2023 Jul 21. doi: 10.1007/s00277-023-05356.
    PubMed     Abstract available


  99. NIU D, Zhao Y, Wang J, Ye E, et al
    Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years.
    Ann Hematol. 2023 Jul 19. doi: 10.1007/s00277-023-05372.
    PubMed     Abstract available


  100. ZHANG Q, Yan H, Ren X, Liu L, et al
    Platelet is an unfavorable prognostic biomarker and associated with leukemia stem cells and immunomodulatory factors in acute myeloid leukemia.
    Ann Hematol. 2023 Jul 15. doi: 10.1007/s00277-023-05367.
    PubMed     Abstract available


  101. ZHOU M, Zhong G, Yu Y, Wang R, et al
    Successful treatment of systemic mastocytosis with acute myeloid leukemia: a case report.
    Ann Hematol. 2023 Jul 11. doi: 10.1007/s00277-023-05341.
    PubMed    


  102. POHLMANN A, Bentgens E, Schulke C, Kuron D, et al
    Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML).
    Ann Hematol. 2023 Jul 10. doi: 10.1007/s00277-023-05353.
    PubMed     Abstract available


  103. SHEN YJ, Zhang Y, Chang J, Wang HF, et al
    CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
    Ann Hematol. 2023;102:1731-1738.
    PubMed     Abstract available


  104. YANG S, Li N, Zhu R, Feng Y, et al
    Impacts of early therapy response, interval to therapy interruption, and cumulative therapy interruption duration on outcome of ibrutinib therapy in relapsed/refractory chronic lymphocytic leukemia.
    Ann Hematol. 2023 Jul 1. doi: 10.1007/s00277-023-05309.
    PubMed     Abstract available


  105. SOBON A, Drozd-Sokolowska J, Paszkiewicz-Kozik E, Poplawska L, et al
    Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
    Ann Hematol. 2023 Jul 1. doi: 10.1007/s00277-023-05304.
    PubMed     Abstract available


    June 2023
  106. VON TRESCKOW J, Heyl N, Robrecht S, Giza A, et al
    Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
    Ann Hematol. 2023 Jun 26. doi: 10.1007/s00277-023-05314.
    PubMed     Abstract available


  107. GRUBER I, Koelbl O, Treutwein M, Zeman F, et al
    Analysis of long-term mortality after total body irradiation-based and melphalan-based chemotherapy conditioning for acute myeloid leukemia.
    Ann Hematol. 2023 Jun 22. doi: 10.1007/s00277-023-05318.
    PubMed     Abstract available


  108. YU WJ, Sun YQ, Xu LP, Zhang XH, et al
    Comparison of outcomes for patients with acute myeloid leukemia undergoing haploidentical stem cell transplantation in first and second complete remission.
    Ann Hematol. 2023 Jun 21. doi: 10.1007/s00277-023-05324.
    PubMed     Abstract available


  109. ZEIDAN AM, Pollyea DA, Borate U, Vasconcelos A, et al
    Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
    Ann Hematol. 2023 Jun 21. doi: 10.1007/s00277-023-05327.
    PubMed    


  110. R C, Malik PS, Sahoo RK, Sharawat S, et al
    Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.
    Ann Hematol. 2023 Jun 15. doi: 10.1007/s00277-023-05280.
    PubMed     Abstract available


  111. TANG X, Wang Y, Zhu Y, Guo Y, et al
    Basic mechanisms and novel potential therapeutic targets for ferroptosis in acute myeloid leukemia.
    Ann Hematol. 2023 Jun 14. doi: 10.1007/s00277-023-05293.
    PubMed     Abstract available


  112. YU Z, Yao Y, Zhang Y, Chen J, et al
    The efficacy of first salvage therapy determines the outcomes of adult patients with type 1 primary refractory acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2023 Jun 10. doi: 10.1007/s00277-023-05313.
    PubMed    


  113. ZANELLI M, Sanguedolce F, Zizzo M, Palicelli A, et al
    Mast cell leukemia associated with essential thrombocythemia: a type of MCL-AHN (MCL-AMN).
    Ann Hematol. 2023 Jun 8. doi: 10.1007/s00277-023-05310.
    PubMed    


  114. CANNAS G, Poutrel S, Heiblig M, Labussiere H, et al
    Sickle cell disease and acute leukemia: one case report and an extensive review.
    Ann Hematol. 2023 Jun 3:1-11. doi: 10.1007/s00277-023-05294.
    PubMed     Abstract available


  115. GEELEN IGP, Gullaksen SE, Ilander MM, Olssen-Stromberg U, et al
    Switching from imatinib to nilotinib plus pegylated interferon-alpha2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.
    Ann Hematol. 2023;102:1395-1408.
    PubMed     Abstract available


  116. DESPREZ C, Kouatchet A, Marchand T, Mear JB, et al
    Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission - a multi-center study.
    Ann Hematol. 2023;102:1383-1393.
    PubMed     Abstract available


    May 2023
  117. JEONG D, Gu JY, Seo MS, Lee JS, et al
    A case of donor cell leukemia driven by a de novo NRAS mutation with complex karyotype.
    Ann Hematol. 2023 May 31. doi: 10.1007/s00277-023-05291.
    PubMed    


  118. TSILIMIDOS G, Blum S
    Comment on: JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.
    Ann Hematol. 2023 May 31. doi: 10.1007/s00277-023-05297.
    PubMed    


  119. HUANG YH, Wan CL, Dai HP, Xue SL, et al
    Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
    Ann Hematol. 2023 May 25. doi: 10.1007/s00277-023-05286.
    PubMed     Abstract available


  120. CAI M, Liu X, Luo A, Yang X, et al
    ADAR1 polymorphisms contribute to increased susceptibility in pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2023 May 22. doi: 10.1007/s00277-023-05285.
    PubMed     Abstract available


  121. HAILU S, Kinde S, Cross M, Tsegaye A, et al
    Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings.
    Ann Hematol. 2023 May 22. doi: 10.1007/s00277-023-05254.
    PubMed     Abstract available


  122. HU M, Liu R, Li J, Zhang L, et al
    Clinical features and prognosis of pediatric acute lymphocytic leukemia with JAK-STAT pathway genetic abnormalities: a case series.
    Ann Hematol. 2023 May 20:1-13. doi: 10.1007/s00277-023-05245.
    PubMed     Abstract available


  123. LUO JS, Zhang XL, Huang DP, Chen YQ, et al
    Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
    Ann Hematol. 2023 May 18. doi: 10.1007/s00277-023-05270.
    PubMed     Abstract available


  124. ZHANG Q, Huang MJ, Wang HY, Wu Y, et al
    A novel prognostic nomogram for adult acute lymphoblastic leukemia: a comprehensive analysis of 321 patients.
    Ann Hematol. 2023 May 13. doi: 10.1007/s00277-023-05267.
    PubMed     Abstract available


  125. LV XY, Li ZJ
    Reduced plasma coagulation factor XIII in patients with acute leukemia in remission during consolidation chemotherapy cycles.
    Ann Hematol. 2023 May 9. doi: 10.1007/s00277-023-05261.
    PubMed     Abstract available


  126. FERREIRA APS, Seguro FS, Abdo ARN, Santos FM, et al
    Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response.
    Ann Hematol. 2023 May 9. doi: 10.1007/s00277-023-05242.
    PubMed    


  127. SRINIVASAN S, Ramanathan S, Kumar S, Peyam S, et al
    Prevalence and prognostic significance of IKZF1 deletion in paediatric acute lymphoblastic leukemia: A systematic review and meta-analysis.
    Ann Hematol. 2023 May 8. doi: 10.1007/s00277-023-05250.
    PubMed     Abstract available


  128. ARAIE H, Tasaki T, Hosono N, Tsujikawa T, et al
    Hematopoietic status of the whole-body bone marrow in hypoplastic acute promyelocytic leukemia as evaluated by (18)F-FLT PET/MRI.
    Ann Hematol. 2023 May 8. doi: 10.1007/s00277-023-05224.
    PubMed    


  129. ASHOUB MH, Naseri A, Mohammadi P, Mohammadi M, et al
    Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis.
    Ann Hematol. 2023 May 3. doi: 10.1007/s00277-023-05246.
    PubMed     Abstract available


  130. ALGHANDOUR R, Sakr DH, Shaaban Y
    Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article.
    Ann Hematol. 2023 May 2. doi: 10.1007/s00277-023-05241.
    PubMed     Abstract available


  131. PAN Z, Wang L, Fu W, Jiang C, et al
    Pediatric chemotherapy versus allo-HSCT for adolescent and adult Philadelphia chromosome-negative ALL in first complete remission: a meta-analysis.
    Ann Hematol. 2023;102:1131-1140.
    PubMed     Abstract available


  132. KOSCHADE SE, Stratmann JA, Zeiner PS, Finkelmeier F, et al
    Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience.
    Ann Hematol. 2023;102:1045-1052.
    PubMed     Abstract available


  133. ARMSTRONG C, Au WY, Ma ESK, Wong SHM, et al
    Sustained spontaneous remission in KMT2A-MLLT3 mutated myeloid sarcoma.
    Ann Hematol. 2023;102:1271-1274.
    PubMed    


  134. XIE W, Liang Z, Wang Q, Wang B, et al
    An adult case of systemic lupus erythematosus and cerebral vasculitis after umbilical cord blood transplantation for acute myeloid leukemia.
    Ann Hematol. 2023 May 1. doi: 10.1007/s00277-023-05229.
    PubMed    


  135. YAMASAKI S, Mizuno S, Iwasaki M, Seo S, et al
    Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics.
    Ann Hematol. 2023 May 1. doi: 10.1007/s00277-023-05243.
    PubMed     Abstract available


    April 2023
  136. TAN KW, Zhu YY, Qiu QC, Wang M, et al
    Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
    Ann Hematol. 2023 Apr 27. doi: 10.1007/s00277-023-05236.
    PubMed     Abstract available


  137. YIGIT KAYA S, Bektas S, Askin AE, Balik Aydin B, et al
    Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient.
    Ann Hematol. 2023 Apr 26. doi: 10.1007/s00277-023-05231.
    PubMed    


  138. LUCIANO L, Latagliata R, Gugliotta G, Annunziata M, et al
    Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
    Ann Hematol. 2023 Apr 20. doi: 10.1007/s00277-023-05159.
    PubMed     Abstract available


  139. DUDA K, Wieczorkiewicz-Kabut A, Koclega A, Zielinska P, et al
    Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience.
    Ann Hematol. 2023 Apr 19. doi: 10.1007/s00277-023-05226.
    PubMed     Abstract available


  140. MASETTI R, Muratore E, Gori D, Prete A, et al
    Response to: meta-analysis on allogeneic transplant for treating pediatric patients with acute myeloid leukemia in first remission: reanalysis of primary data.
    Ann Hematol. 2023 Apr 15. doi: 10.1007/s00277-023-05219.
    PubMed    


  141. FERREIRA APS, Seguro FS, Abdo ARN, Santos FM, et al
    Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
    Ann Hematol. 2023 Apr 13. doi: 10.1007/s00277-023-05189.
    PubMed     Abstract available


  142. CHEN K, Hendrie PC, Naresh KN
    Aleukemic mast cell leukemia, well-differentiated and chronic type.
    Ann Hematol. 2023 Apr 4. doi: 10.1007/s00277-023-05195.
    PubMed    


  143. HAUPTMANN L, Midic D, Eigendorff F, Malouhi A, et al
    Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia.
    Ann Hematol. 2023 Apr 4. doi: 10.1007/s00277-023-05208.
    PubMed    


  144. PERRONE S, Capria S, Bernardi M, Marchesi F, et al
    Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients.
    Ann Hematol. 2023;102:769-775.
    PubMed     Abstract available


  145. BACCELLI F, Leardini D, Cerasi S, Messelodi D, et al
    ERCC6L2-related disease: a novel entity of bone marrow failure disorder with high risk of clonal evolution.
    Ann Hematol. 2023;102:699-705.
    PubMed     Abstract available


  146. KURON D, Pohlmann A, Angenendt L, Kessler T, et al
    Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.
    Ann Hematol. 2023;102:755-760.
    PubMed     Abstract available


    March 2023
  147. GANDO Y, Yasu T
    Real-world treatment patterns of venetoclax and azacytidine therapy in Japanese patients with acute myeloid leukemia.
    Ann Hematol. 2023 Mar 29. doi: 10.1007/s00277-023-05201.
    PubMed    


  148. LAZZAROTTO D, Tanasi I, Vitale A, Piccini M, et al
    Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation:
    Ann Hematol. 2023 Mar 24. doi: 10.1007/s00277-023-05162.
    PubMed     Abstract available


  149. ZHUANG H, Li F, Xu Y, Pei R, et al
    Loss of IRF8 inhibits the growth of acute myeloid leukemia cells.
    Ann Hematol. 2023 Mar 23. doi: 10.1007/s00277-023-05156.
    PubMed     Abstract available


  150. TOSONI L, Fabbro D, Pizzano U, Mullai R, et al
    JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response.
    Ann Hematol. 2023 Mar 22. doi: 10.1007/s00277-023-05187.
    PubMed    


  151. LIANG X, Fu W, Peng Y, Duan J, et al
    Lycorine induces apoptosis of acute myeloid leukemia cells and inhibits triglyceride production via binding and targeting FABP5.
    Ann Hematol. 2023 Mar 21. doi: 10.1007/s00277-023-05169.
    PubMed     Abstract available


  152. ITONAGA H, Miyazaki Y, Aoki K, Shingai N, et al
    Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical relatives in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukemia: a propensity score analysis of a nationwide database.
    Ann Hematol. 2023 Mar 15. doi: 10.1007/s00277-023-05167.
    PubMed     Abstract available


  153. SHARMA A, Yang J, Singh V
    Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States.
    Ann Hematol. 2023 Mar 14. doi: 10.1007/s00277-023-05154.
    PubMed     Abstract available


  154. BRECCIA M, Olimpieri PP, Celant S, Olimpieri OM, et al
    Effectiveness and management of ponatinib as second-line treatment in chronic myeloid leukemia: an analysis from the monitoring registries of the Italian medicines agency (AIFA).
    Ann Hematol. 2023 Mar 13. doi: 10.1007/s00277-023-05168.
    PubMed    


  155. HELLOU T, Cohen O, Avigdor A, Amitai I, et al
    The occurrence of thrombosis during intensive chemotherapy treatment for acute myeloid leukemia patients does not impact on long-term survival.
    Ann Hematol. 2023 Mar 11. doi: 10.1007/s00277-023-05158.
    PubMed     Abstract available


  156. FERRARI LC, Rivas MM, Navickas AB, Dick H, et al
    PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
    Ann Hematol. 2023 Mar 9. doi: 10.1007/s00277-023-05151.
    PubMed     Abstract available


  157. CHANG J, Shen YJ, Shi T, Wang HF, et al
    Venetoclax and blinatumomab based chemotherapy-free treatment in a patient with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2023 Mar 9. doi: 10.1007/s00277-023-05127.
    PubMed    


  158. VAN DER ZOUWEN B, Koster EAS, von dem Borne PA, Oosten LEM, et al
    Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients.
    Ann Hematol. 2023 Mar 7. doi: 10.1007/s00277-023-05145.
    PubMed     Abstract available


  159. MESSORI A, Hyeraci G
    Meta-analysis on allogeneic transplant for treating pediatric patients with acute myeloid leukemia in first remission: reanalysis of primary data.
    Ann Hematol. 2023 Mar 6. doi: 10.1007/s00277-023-05101.
    PubMed    


  160. REED DR, Wooster M, Isom S, Ellis LR, et al
    Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen.
    Ann Hematol. 2023 Mar 1. doi: 10.1007/s00277-023-05141.
    PubMed     Abstract available


  161. MAO S, Qian Y, Wei W, Lin X, et al
    FLOT1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosis.
    Ann Hematol. 2023;102:583-595.
    PubMed     Abstract available


  162. NIEDERWIESER D, Lang T, Krahl R, Heinicke T, et al
    Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study.
    Ann Hematol. 2023;102:547-561.
    PubMed     Abstract available


  163. PARK W, Byun JM, Hong J, Kim I, et al
    Comparison of the effect of DLI according to cell sources in relapsed AML after allogeneic stem cell transplantation.
    Ann Hematol. 2023;102:629-639.
    PubMed     Abstract available


    February 2023
  164. SIMKOVIC M, Turcsanyi P, Spacek M, Mihalyova J, et al
    COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group.
    Ann Hematol. 2023 Feb 27:1-7. doi: 10.1007/s00277-023-05147.
    PubMed     Abstract available


  165. MATSUDA K, Yoshida T, Sugimoto K
    High susceptibility of febrile neutropenia in Japanese patients receiving venetoclax plus azacitidine therapy for acute myeloid leukemia.
    Ann Hematol. 2023 Feb 23. doi: 10.1007/s00277-023-05143.
    PubMed    


  166. AMMAD UD DIN M, Mahmud A, Mostafa M, Shahzad M, et al
    Risks and outcomes of hospitalizations in patients with chronic lymphocytic leukemia admitted with immune thrombocytopenia: an analysis of the National Inpatient Sample Database.
    Ann Hematol. 2023 Feb 13. doi: 10.1007/s00277-023-05133.
    PubMed     Abstract available


  167. CERRANO M, Chevret S, Raffoux E, Rabian F, et al
    Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis.
    Ann Hematol. 2023 Feb 11:1-8. doi: 10.1007/s00277-023-05119.
    PubMed     Abstract available


  168. YUE K, Gao H, Liang S, Wu N, et al
    Improved Vdelta2(+) T cells recovery correlates to reduced incidences of mortality and relapse in acute myeloid leukemia after hematopoietic transplantation.
    Ann Hematol. 2023 Feb 10. doi: 10.1007/s00277-023-05125.
    PubMed     Abstract available


  169. LI S, Gao Y, Li F, Zheng Y, et al
    Value of the FDP/FIB ratio in predicting early severe bleeding events in patients with newly diagnosed acute promyelocytic leukemia.
    Ann Hematol. 2023 Feb 7. doi: 10.1007/s00277-023-05122.
    PubMed     Abstract available


  170. ZHANG R, Liu Y, Song H, Tan Y, et al
    Clonal evolution analysis of a rare acute promyelocytic leukemia patient transforming from essential thrombocythemia.
    Ann Hematol. 2023 Feb 7. doi: 10.1007/s00277-023-05112.
    PubMed    


  171. ZHANG T, Zhou H, Xu M, Qian C, et al
    Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia.
    Ann Hematol. 2023 Feb 6. doi: 10.1007/s00277-023-05110.
    PubMed    


  172. SUN Y, Wang Q, Zhang X, Zhang Z, et al
    Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia.
    Ann Hematol. 2023 Feb 3. doi: 10.1007/s00277-023-05106.
    PubMed     Abstract available


  173. ZEIDAN AM, Pollyea DA, Borate U, Vasconcelos A, et al
    Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.
    Ann Hematol. 2023 Feb 3. doi: 10.1007/s00277-023-05109.
    PubMed     Abstract available


  174. DE LA GARZA-SALAZAR F, Gomez-De Leon A, Gomez-Almaguer D, Colunga-Pedraza PR, et al
    Vinblastine as a bridge to 7 + 3 in acute myeloid leukaemia.
    Ann Hematol. 2023;102:487-489.
    PubMed    


  175. KLEMENT P, Fiedler W, Gabdoulline R, Dallmann LK, et al
    Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy.
    Ann Hematol. 2023;102:323-328.
    PubMed     Abstract available


  176. KUNDU R, Seeger R, Elfassy MD, Rozenberg D, et al
    The association between nutritional risk index and ICU outcomes across hematologic malignancy patients with acute respiratory failure.
    Ann Hematol. 2023;102:439-445.
    PubMed     Abstract available


  177. HUANG J, Zhu Y, Li J, Yang G, et al
    The KMT2A rearrangement is an early event prior to KMT2A-PTD in AML patients with both molecular aberrations.
    Ann Hematol. 2023;102:495-497.
    PubMed    



  178. ACUTE LEUKEMIAS XVIII Biology and Treatment Strategies.
    Ann Hematol. 2023;102.
    PubMed    


    January 2023
  179. STANULLA M, Schewe DM, Bornhauser B, Bourquin JP, et al
    Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia.
    Ann Hematol. 2023 Jan 18. doi: 10.1007/s00277-023-05083.
    PubMed    


  180. AIBA M, Shigematsu A, Suzuki T, Miyagishima T, et al
    Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia.
    Ann Hematol. 2023 Jan 16. doi: 10.1007/s00277-023-05102.
    PubMed     Abstract available


  181. CHEUNG CYM, Leung RYY, Tam AR, Sim JPY, et al
    Disseminated Mycobacterium haemophilum infection during alemtuzumab treatment of T-cell prolymphocytic leukemia.
    Ann Hematol. 2023 Jan 13. doi: 10.1007/s00277-022-05053.
    PubMed    


  182. FU W, Hu Y, Lu G, Xu L, et al
    Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment.
    Ann Hematol. 2023 Jan 12. doi: 10.1007/s00277-023-05096.
    PubMed     Abstract available


  183. CAO HY, Wan CL, Xue SL
    Comparing the efficacy of salvage regimens for relapsed/refractory B-cell acute lymphoblastic leukaemia: a systematic review and network meta-analysis.
    Ann Hematol. 2023;102:155-165.
    PubMed     Abstract available


  184. HUANG W, Xue S, Zhang Y, Liu F, et al
    Refractory hepatosplenic T-cell lymphoma was successfully treated with salvage allogeneic hematopoietic stem cell transplantation combined with enhanced myeloablative preconditioning.
    Ann Hematol. 2023;102:175-180.
    PubMed     Abstract available


  185. KATAMESH B, Nanaa A, He R, Viswanatha D, et al
    Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms.
    Ann Hematol. 2023;102:211-212.
    PubMed    


    December 2022
  186. LI R, Wang Z, Zhang Y, Guo M, et al
    Cytogenetic evolution predicts a poor prognosis in acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2022 Dec 21. doi: 10.1007/s00277-022-05061.
    PubMed     Abstract available


  187. CELLINI A, Scarmozzino F, Friziero A, Trimarco V, et al
    Persistent splenomegaly due to littoral cell angiomatosis in venetoclax-induced undetectable minimal residual disease of chronic lymphocytic leukemia.
    Ann Hematol. 2022 Dec 21. doi: 10.1007/s00277-022-05067.
    PubMed    


  188. THAKRAL D, Singh VK, Gupta R, Jha N, et al
    Integrated single-cell transcriptome analysis of CD34 + enriched leukemic stem cells revealed intra- and inter-patient transcriptional heterogeneity in pediatric acute myeloid leukemia.
    Ann Hematol. 2022 Dec 17. doi: 10.1007/s00277-022-05021.
    PubMed     Abstract available


  189. KONRAT J, Rosler W, Roiss M, Meier-Abt F, et al
    BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2.
    Ann Hematol. 2022 Dec 10:1-4. doi: 10.1007/s00277-022-05026.
    PubMed     Abstract available


  190. YANG TT, Song XL, Zhao YM, Ye BD, et al
    Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients.
    Ann Hematol. 2022;101:2731-2741.
    PubMed     Abstract available


  191. DIAMANTOPOULOS PT, Kontandreopoulou CN, Stafylidis C, Vlachopoulou D, et al
    Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection.
    Ann Hematol. 2022;101:2711-2717.
    PubMed     Abstract available


  192. ZHANG JY, Li Y, Ma YS, Sun XJ, et al
    Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases.
    Ann Hematol. 2022;101:2617-2625.
    PubMed     Abstract available


  193. NAJIMA Y, Tachibana T, Takeda Y, Koda Y, et al
    Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study.
    Ann Hematol. 2022;101:2719-2729.
    PubMed     Abstract available


  194. TAN X, Yuan H, Li D, Sun X, et al
    Clinical and prognostic role of 2-[(18)F]FDG PET/CT and sarcopenia in treatment-naive patients with T-cell lymphoblastic lymphoma.
    Ann Hematol. 2022;101:2699-2709.
    PubMed     Abstract available


    November 2022
  195. SULEMAN A, Tsui H, Ghorab Z, Lam PW, et al
    EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia.
    Ann Hematol. 2022 Nov 28. doi: 10.1007/s00277-022-05060.
    PubMed    


  196. SUN H, Yan H, Yan Z, Zhu Y, et al
    Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT.
    Ann Hematol. 2022 Nov 24. doi: 10.1007/s00277-022-05047.
    PubMed    


  197. BERDEL AF, Koch R, Gerss J, Hentrich M, et al
    A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
    Ann Hematol. 2022 Nov 18. pii: 10.1007/s00277-022-05025.
    PubMed     Abstract available


  198. ZHANG YW, Su L, Tan YH, Lin H, et al
    Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
    Ann Hematol. 2022 Nov 15. pii: 10.1007/s00277-022-05033.
    PubMed     Abstract available


  199. DELEHAYE F, Rouger J, Brossier D, Suttorp M, et al
    Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course.
    Ann Hematol. 2022 Nov 12. pii: 10.1007/s00277-022-05024.
    PubMed     Abstract available


  200. WELLER MC, Haralambieva E, Buhler MM, Benz R, et al
    CALR loss-of-heterozygosity as a potential driver for extramedullary AML.
    Ann Hematol. 2022;101:2571-2573.
    PubMed    


  201. ZHU Y, Dai Y, Tang X
    Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.
    Ann Hematol. 2022;101:2525-2528.
    PubMed    


    October 2022
  202. CORDELLA S, Parisotto A, Bettelli F, Morselli M, et al
    Feasibility of autologous peripheral blood stem cell mobilization and harvest in adult patients with FLT3-mutated acute myeloid leukemia receiving chemotherapy combined with midostaurin: a single-center experience.
    Ann Hematol. 2022 Oct 20. pii: 10.1007/s00277-022-05013.
    PubMed    


  203. PARK HS, Kim HK, Kim HS, Yang Y, et al
    The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications.
    Ann Hematol. 2022 Oct 12. pii: 10.1007/s00277-022-05002.
    PubMed     Abstract available


  204. TRIGUERO A, Pedraza A, Perez-Encinas M, Mata-Vazquez MI, et al
    Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
    Ann Hematol. 2022;101:2231-2239.
    PubMed     Abstract available


  205. LIN SC, Yao CY, Hsu CA, Lin CT, et al
    Functional association of NR4A3 downregulation with impaired differentiation in myeloid leukemogenesis.
    Ann Hematol. 2022;101:2209-2218.
    PubMed     Abstract available


  206. WATANABE N, Takaku T, Fujioka I, Tsuchiya S, et al
    Bosutinib-induced late-onset severe liver injury preceded by eosinophilia.
    Ann Hematol. 2022;101:2257-2262.
    PubMed     Abstract available


  207. ZHANG H, Zhan Q, Wang X, Gao F, et al
    TLS/FUS-ERG fusion gene in acute leukemia and myelodysplastic syndrome evolved to acute leukemia: report of six cases and a literature review.
    Ann Hematol. 2022 Oct 1. pii: 10.1007/s00277-022-04979.
    PubMed     Abstract available


    September 2022
  208. SPATH C, Schonau M, Gaubert S, Neumann T, et al
    Rhabdomyolysis induced by nelarabine.
    Ann Hematol. 2022;101:2111-2112.
    PubMed    


    August 2022
  209. HARADA N, Makuuchi Y, Kuno M, Takakuwa T, et al
    Intramural esophageal hematoma precipitated by acquired factor XI deficiency in a patient with relapsed T cell prolymphocytic leukemia after allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2022 Aug 31. pii: 10.1007/s00277-022-04970.
    PubMed    


  210. SAUGUES S, Lambert C, Daguenet E, Ansah HJ, et al
    Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
    Ann Hematol. 2022 Aug 30. pii: 10.1007/s00277-022-04955.
    PubMed     Abstract available


  211. MASETTI R, Muratore E, Gori D, Prete A, et al
    Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis.
    Ann Hematol. 2022 Aug 30. pii: 10.1007/s00277-022-04965.
    PubMed     Abstract available


  212. LUNA A, Perez-Lamas L, Boque C, Giraldo P, et al
    Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia.
    Ann Hematol. 2022 Aug 23. pii: 10.1007/s00277-022-04932.
    PubMed     Abstract available


  213. GIAMMARCO S, Bellesi S, Metafuni E, Rossi M, et al
    Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation.
    Ann Hematol. 2022 Aug 22. pii: 10.1007/s00277-022-04962.
    PubMed    


  214. YANADA M
    Treatment for relapsed acute promyelocytic leukemia.
    Ann Hematol. 2022 Aug 16. pii: 10.1007/s00277-022-04954.
    PubMed     Abstract available


  215. ZHAI Y, Shang J, Yao W, Wu D, et al
    Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.
    Ann Hematol. 2022 Aug 15. pii: 10.1007/s00277-022-04942.
    PubMed    


  216. CHIRICHES C, Khan D, Wieske M, Guillen N, et al
    Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
    Ann Hematol. 2022 Aug 8. pii: 10.1007/s00277-022-04905.
    PubMed     Abstract available


  217. BOEREKAMPS A, Hamberg P, Libourel EJ
    Discontinuation of azacitidine in acute myeloid leukemia: a feasible option?
    Ann Hematol. 2022 Aug 4. pii: 10.1007/s00277-022-04939.
    PubMed    


  218. DONG T, Wu N, Gao H, Liang S, et al
    CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vdelta2(+) T cell cytotoxicity.
    Ann Hematol. 2022 Aug 3. pii: 10.1007/s00277-022-04930.
    PubMed     Abstract available


  219. ROTTERDAM J, Thiaucourt M, Weiss C, Schwaab J, et al
    Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases.
    Ann Hematol. 2022;101:1825-1834.
    PubMed     Abstract available


  220. WANG W, Zhang Y, Zhao D, Zhang W, et al
    Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.
    Ann Hematol. 2022;101:1869-1872.
    PubMed    


    July 2022
  221. AHMED MZ, Venkatadasari I, Dyer S, Wall K, et al
    Clonal evolution in adult TCF3::HLF-positive acute lymphoblastic leukemia undergoing stem cell transplantation.
    Ann Hematol. 2022 Jul 30. pii: 10.1007/s00277-022-04941.
    PubMed    


  222. SEVINDIK OG, Mergen M, Mergen S, Mutlu YG, et al
    To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission.
    Ann Hematol. 2022 Jul 29. pii: 10.1007/s00277-022-04938.
    PubMed    


  223. SHIMONY S, Canaani J, Kugler E, Nachmias B, et al
    Correction to: Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a realworld, multicenter, matched analysis.
    Ann Hematol. 2022 Jul 23. pii: 10.1007/s00277-022-04929.
    PubMed    


  224. SHIN WY, Kim JA, Yoon SY, Bang HI, et al
    Co-existence of a novel translocation t(11;22)(q23;q12.1) with PML-RARA in acute promyelocytic leukemia: a case report.
    Ann Hematol. 2022 Jul 2. pii: 10.1007/s00277-022-04911.
    PubMed    


  225. WU X, Cheng L, Liu X, Sun Y, et al
    Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia.
    Ann Hematol. 2022;101:1493-1498.
    PubMed     Abstract available


  226. HIRANO M, Tamba M, Inoue N, Ikegami M, et al
    Durable response of therapy-related MDS/AML with concomitant Waldenstrom's macroglobulinemia treated with venetoclax and azacitidine.
    Ann Hematol. 2022;101:1587-1589.
    PubMed    


    June 2022
  227. YIN J, Zhu F, Zhang ZB, Wang Q, et al
    Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation.
    Ann Hematol. 2022 Jun 29. pii: 10.1007/s00277-022-04897.
    PubMed    


  228. SHIMONY S, Canaani J, Kugler E, Nachmias B, et al
    Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
    Ann Hematol. 2022 Jun 24. pii: 10.1007/s00277-022-04895.
    PubMed     Abstract available


  229. WOLACH O, Frisch A, Shargian L, Yeshurun M, et al
    Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis.
    Ann Hematol. 2022 Jun 23. pii: 10.1007/s00277-022-04883.
    PubMed     Abstract available


  230. KATHPALIA M, Mishra P, Bajpai R, Bhurani D, et al
    Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Ann Hematol. 2022 Jun 21. pii: 10.1007/s00277-022-04880.
    PubMed     Abstract available


  231. YANG X, Zhang R, Zhang Z
    The rare IRF2BP2-RARA fusion in acute promyelocytic leukemia.
    Ann Hematol. 2022 Jun 15. pii: 10.1007/s00277-022-04874.
    PubMed    


  232. BRAITSCH K, Schwarz A, Koch K, Hubbuch M, et al
    Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis.
    Ann Hematol. 2022;101:1311-1319.
    PubMed     Abstract available


  233. WATTEBLED KJ, Drumez E, Coiteux V, Magro L, et al
    Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation.
    Ann Hematol. 2022;101:1321-1331.
    PubMed     Abstract available


  234. LEUNG WY, Cheuk DK, Cheng FW, Leung AW, et al
    Outcome prediction of chronic myeloid leukemia (CML) in children.
    Ann Hematol. 2022 Jun 1. pii: 10.1007/s00277-022-04852.
    PubMed     Abstract available


    May 2022
  235. OCHS MA, Marini BL, Perissinotti AJ, Foucar CE, et al
    Oncology stewardship in acute myeloid leukemia.
    Ann Hematol. 2022 May 26. pii: 10.1007/s00277-022-04872.
    PubMed     Abstract available


  236. SAITO K, Ichikawa S, Ohtomo R, Hatta S, et al
    Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during induction chemotherapy for acute promyelocytic leukemia.
    Ann Hematol. 2022 May 25. pii: 10.1007/s00277-022-04875.
    PubMed    


  237. KOSCHADE SE, Stratmann JA, Finkelmeier F, Wagner S, et al
    Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations.
    Ann Hematol. 2022 May 20. pii: 10.1007/s00277-022-04862.
    PubMed     Abstract available


  238. ZENG Q, Xiang B, Liu Z
    Autologous hematopoietic stem cell transplantation followed by interleukin-2 for adult acute myeloid leukemia patients with favorable or intermediate risk after complete remission.
    Ann Hematol. 2022 May 16. pii: 10.1007/s00277-022-04863.
    PubMed     Abstract available


  239. PODVIN B, Guermouche H, Roynard P, Goursaud L, et al
    Subclonal acquisition of a BCR::ABL1 fusion in a chronic myelomonocytic leukemia.
    Ann Hematol. 2022 May 13. pii: 10.1007/s00277-022-04861.
    PubMed    


  240. SHARMA R, Jani C
    Mapping incidence and mortality of leukemia and its subtypes in 21 world regions in last three decades and projections to 2030.
    Ann Hematol. 2022 May 10. pii: 10.1007/s00277-022-04843.
    PubMed     Abstract available


  241. BOQUOI A, Banahan SM, Mohring A, Savickaite I, et al
    Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.
    Ann Hematol. 2022;101:1031-1038.
    PubMed     Abstract available


  242. HOFER KD, Schanz U, Schwotzer R, Nair G, et al
    Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10 years.
    Ann Hematol. 2022;101:1097-1106.
    PubMed     Abstract available


  243. WANG Y, Hou W, Li H, Tian X, et al
    Analysis of risk factors for early death in patients with acute promyelocytic leukaemia treated with arsenic trioxide.
    Ann Hematol. 2022;101:1039-1047.
    PubMed     Abstract available


  244. SATO M, Yasunaga M, Ohzu M, Toyama K, et al
    Successful diagnosis of veno-occlusive disease caused by inotuzumab ozogamicin through minimal-invasive angiography: a case report.
    Ann Hematol. 2022;101:1153-1155.
    PubMed    


  245. HAZENBERG CLE, Diepstra A, Santing M, Huls GA, et al
    Bone marrow necrosis as complication of treatment with all-trans retinoic acid and arsenic trioxide: case report and implications for treatment.
    Ann Hematol. 2022;101:1133-1134.
    PubMed    


  246. SHALLIS RM, Pucar D, Perincheri S, Gore SD, et al
    Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy.
    Ann Hematol. 2022;101:1145-1147.
    PubMed    


    April 2022
  247. SEKERES MA, Schuster M, Joris M, Krauter J, et al
    A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
    Ann Hematol. 2022 Apr 30. pii: 10.1007/s00277-022-04853.
    PubMed     Abstract available


  248. LI Y, Tang T, Xiao J, Li B, et al
    Comparative efficacy and safety of eleven induction chemotherapy regimens for young adult patients with newly diagnosed acute myeloid leukemia: a network meta-analysis.
    Ann Hematol. 2022 Apr 20. pii: 10.1007/s00277-022-04840.
    PubMed     Abstract available


  249. WANG Y, Wang T, Yu Y, Wang Q, et al
    Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
    Ann Hematol. 2022 Apr 18. pii: 10.1007/s00277-022-04795.
    PubMed     Abstract available


  250. LAUW MIS, Hakim N, Arora S, Prakash S, et al
    A case of plasma cell neoplasm-associated chronic neutrophilic leukemia with ASXL1 and JAK2V617F mutations.
    Ann Hematol. 2022 Apr 14. pii: 10.1007/s00277-022-04834.
    PubMed    


  251. GREINER SM, Marklin M, Holzmayer S, Kaban K, et al
    Identification of CD105 (endoglin) as novel risk marker in CLL.
    Ann Hematol. 2022;101:773-780.
    PubMed     Abstract available


    March 2022
  252. MORIMOTO S, Kondo T, Taya T, Matsuo H, et al
    Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA.
    Ann Hematol. 2022 Mar 26. pii: 10.1007/s00277-022-04825.
    PubMed    


  253. LI Y, Dai H, Yao D, Gao X, et al
    Central nervous system relapse of acute promyelocytic leukemia treated by oral Venetoclax with Azacitidine achieved complete remission.
    Ann Hematol. 2022 Mar 26. pii: 10.1007/s00277-022-04823.
    PubMed    


  254. TSUSHIMA T, Sato N, Guo YM, Uchiyama S, et al
    Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2022 Mar 24. pii: 10.1007/s00277-022-04796.
    PubMed    


  255. CHAUHAN P, Gupta A, Gopinathan M, Sanjeev, et al
    Real-world challenges in the management of acute myeloid leukemia: a single-center experience from North India.
    Ann Hematol. 2022 Mar 24. pii: 10.1007/s00277-022-04814.
    PubMed     Abstract available


  256. UMINSKI K, Khalife R, Kekre N, Tinmouth A, et al
    Acquired hemophilia A following allogeneic stem cell transplantation for acute lymphoblastic leukemia.
    Ann Hematol. 2022 Mar 21. pii: 10.1007/s00277-022-04819.
    PubMed    


  257. CAETANO DOS SANTOS FL, Michalek IM, Wojciechowska U, Didkowska J, et al
    Improved survival of Burkitt lymphoma/leukemia patients: observations from Poland, 1999-2020.
    Ann Hematol. 2022 Mar 15. pii: 10.1007/s00277-022-04758.
    PubMed     Abstract available


  258. BI X, French Z, Palmisiano N, Wen KY, et al
    The prognostic impact of cigarette smoking on survival in acute myeloid leukemia with TP53 mutations and/or 17p deletions.
    Ann Hematol. 2022 Mar 14. pii: 10.1007/s00277-022-04812.
    PubMed     Abstract available


  259. ROBIN JB, Theron A, Quittet P, Exbrayat C, et al
    Discontinuation of tyrosine kinase inhibitor in chronic myeloid leukemia: a retrospective cohort in east occitania.
    Ann Hematol. 2022 Mar 12. pii: 10.1007/s00277-022-04779.
    PubMed     Abstract available


  260. ROSETTI M, De la Salle B, Farneti G, Clementoni A, et al
    The added value of digital morphological analysis in the evaluation of peripheral blood films: the report of an UKNEQAS external quality assessment sample.
    Ann Hematol. 2022;101:729-730.
    PubMed    


    February 2022
  261. HERMEL DJ, Cheng B, Bhangoo MS, Burian C, et al
    Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine.
    Ann Hematol. 2022 Feb 26. pii: 10.1007/s00277-022-04800.
    PubMed     Abstract available


  262. BAYSAL M, Gursoy V, Hunutlu FC, Erkan B, et al
    The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study.
    Ann Hematol. 2022 Feb 21. pii: 10.1007/s00277-022-04798.
    PubMed     Abstract available


  263. ROBAK E, Jesionek-Kupnicka D, Stelmach P, Kupnicki P, et al
    Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab.
    Ann Hematol. 2022 Feb 21. pii: 10.1007/s00277-022-04753.
    PubMed    


  264. TANG G, Zou Y, Wang SA, Borthakur G, et al
    3'CBFB deletion in CBFB-rearranged acute myeloid leukemia retains morphological features associated with inv(16), but patients have higher risk of relapse and may require stem cell transplant.
    Ann Hematol. 2022 Feb 20. pii: 10.1007/s00277-022-04767.
    PubMed     Abstract available


  265. FU W, Huang A, Tang G, Yang J, et al
    A case report of BCR-ABL1 rearrangement in de novo adult T-cell lymphoblastic leukemia/lymphoma with normal karyotype.
    Ann Hematol. 2022 Feb 14. pii: 10.1007/s00277-022-04791.
    PubMed    


  266. MARTELLA F, Cerrano M, Di Cuonzo D, Secreto C, et al
    Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.
    Ann Hematol. 2022 Feb 7. pii: 10.1007/s00277-022-04770.
    PubMed     Abstract available


  267. KEREN-FROIM N, Heering G, Sharvit G, Zlotnik M, et al
    ELN 2017 classification significantly impacts the risk of early death in acute myeloid leukemia patients receiving intensive induction chemotherapy.
    Ann Hematol. 2022;101:309-316.
    PubMed     Abstract available


  268. SCHMITZ-FEUERHAKE I, Frentzel-Beyme R, Wolff R
    Non-Hodgkin lymphomas and ionizing radiation: case report and review of the literature.
    Ann Hematol. 2022;101:243-250.
    PubMed     Abstract available


  269. DI GIACOMO D, Quintini M, Pierini V, Pellanera F, et al
    Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement.
    Ann Hematol. 2022;101:297-307.
    PubMed     Abstract available


  270. DUNN WG, Gu MS, Fabre MA, Cooper J, et al
    The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients.
    Ann Hematol. 2022;101:443-445.
    PubMed    


    January 2022
  271. BAEK J, Kim MK, Gu MJ
    Myelolipoma/extramedullary hematopoiesis within adrenal cortical adenoma increased in size during chronic myelogenous leukemia treatment.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-022-04768.
    PubMed    


  272. FREDMAN D, Moshe Y, Wolach O, Heering G, et al
    Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-021-04738.
    PubMed     Abstract available


  273. QIU L, Nunez CA, Tang G, Cuglievan B, et al
    A rare case of acute megakaryoblastic leukemia with t(11;17)(q23;q21) and KMT2A::MLLT6 fusion.
    Ann Hematol. 2022 Jan 28. pii: 10.1007/s00277-022-04769.
    PubMed    


  274. MELLADO-GAZQUEZ A, Gomez-Nunez MR, Jurado-Herrera S, Prats-Martin C, et al
    Multiple erythrophagocytosis by erythroid blasts in acute myeloid leukemia with BCR-ABL1.
    Ann Hematol. 2022 Jan 27. pii: 10.1007/s00277-021-04742.
    PubMed    


  275. DUTTA S, Moritz J, Pregartner G, Thallinger GG, et al
    Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
    Ann Hematol. 2022 Jan 26. pii: 10.1007/s00277-022-04766.
    PubMed     Abstract available


  276. MAO YY, Cai HC, Shen KN, Chang L, et al
    Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study.
    Ann Hematol. 2022 Jan 17. pii: 10.1007/s00277-022-04764.
    PubMed     Abstract available


  277. ONISHI A, Fuji S, Kitano S, Maeshima AM, et al
    Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma.
    Ann Hematol. 2022 Jan 15. pii: 10.1007/s00277-022-04760.
    PubMed     Abstract available


  278. TISO F, Koorenhof-Scheele TN, Huys E, Martens JHA, et al
    Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML.
    Ann Hematol. 2022 Jan 13. pii: 10.1007/s00277-021-04747.
    PubMed     Abstract available


  279. HARADA K, Mizuno S, Yano S, Takami A, et al
    Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia.
    Ann Hematol. 2022 Jan 6. pii: 10.1007/s00277-021-04731.
    PubMed     Abstract available


  280. ZEIDAN AM, DeAngelo DJ, Palmer J, Seet CS, et al
    Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
    Ann Hematol. 2022 Jan 4. pii: 10.1007/s00277-021-04734.
    PubMed     Abstract available


  281. KONUMA T, Ooi J, Nagayama H, Tomonari A, et al
    Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.
    Ann Hematol. 2022;101:177-189.
    PubMed     Abstract available


  282. GUPTA A, Desai N, Sanjeev, Chauhan P, et al
    Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India.
    Ann Hematol. 2022;101:69-79.
    PubMed     Abstract available


  283. SAKURAI M, Nannya Y, Yamazaki R, Yamaguchi K, et al
    Germline RUNX1 translocation in familial platelet disorder with propensity to myeloid malignancies.
    Ann Hematol. 2022;101:237-239.
    PubMed    


    December 2021
  284. DALELA D, Bledsoe JR, Patel SA
    Clonal IgH gene rearrangements identify Richter's transformation to diffuse large B cell lymphoma.
    Ann Hematol. 2021;100:3075-3077.
    PubMed    


  285. PULIDO-PEREZ A, Bergon-Sendin M, Mateos-Mayo A, Parra-Blanco V, et al
    Cutaneous botryomycosis mimicking ecthyma gangrenosum in a patient treated with ibrutinib.
    Ann Hematol. 2021;100:3065-3066.
    PubMed    


    November 2021
  286. ARCANI R, Colle J, Cauchois R, Koubi M, et al
    Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
    Ann Hematol. 2021;100:2799-2803.
    PubMed     Abstract available


  287. REINERT J, Beitzen-Heineke A, Wethmar K, Stelljes M, et al
    Loss of CD22 expression and expansion of a CD22(dim) subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin.
    Ann Hematol. 2021;100:2727-2732.
    PubMed     Abstract available


  288. MAYER MC, Berg JL, Perfler B, Hatzl S, et al
    miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.
    Ann Hematol. 2021;100:2845-2847.
    PubMed    


    October 2021
  289. STANGANELLI C, Torres DC, Ortega C, Marquez ME, et al
    Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients.
    Ann Hematol. 2021 Oct 28. pii: 10.1007/s00277-021-04703.
    PubMed     Abstract available


  290. MENDES FR, da Silva WF, da Costa Bandeira de Melo R, Silveira DRA, et al
    Predictive factors associated with induction-related death in acute myeloid leukemia in a resource-constrained setting.
    Ann Hematol. 2021 Oct 21. pii: 10.1007/s00277-021-04687.
    PubMed     Abstract available


  291. ZHANG Y, Qian JJ, Shen YJ, Hang SJ, et al
    The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 18. pii: 10.1007/s00277-021-04699.
    PubMed    


  292. HOU HA, Tzeng HE, Liu HY, Chou WC, et al
    Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015.
    Ann Hematol. 2021 Oct 13. pii: 10.1007/s00277-021-04670.
    PubMed     Abstract available


  293. PASVOLSKY O, Shimony S, Ram R, Shimoni A, et al
    Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Ann Hematol. 2021 Oct 9. pii: 10.1007/s00277-021-04693.
    PubMed     Abstract available


  294. UMINSKI K, Khalife R, Fulcher J, Duffett L, et al
    Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia.
    Ann Hematol. 2021 Oct 6. pii: 10.1007/s00277-021-04688.
    PubMed    


  295. CHOI HS, Hong J, Hwang SM, Lee JH, et al
    Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Ann Hematol. 2021;100:2567-2574.
    PubMed     Abstract available


  296. SHAH N, Rakszawski K, Nickolich M, Ehmann C, et al
    Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion.
    Ann Hematol. 2021;100:2585-2592.
    PubMed     Abstract available


  297. BALLO O, Eladly F, Koschade S, Buttner S, et al
    Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy.
    Ann Hematol. 2021;100:2603-2611.
    PubMed     Abstract available


  298. DAS N, Gupta R, Gupta SK, Bakhshi S, et al
    Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
    Ann Hematol. 2021;100:2487-2500.
    PubMed     Abstract available


  299. SAVASAN S, Buck S, Gadgeel M, Poulik J, et al
    Persistent pseudo-Pelger-Huet anomaly.
    Ann Hematol. 2021;100:2661-2663.
    PubMed    


  300. MARRA A, Martino G, Scarpelli N, Perriello V, et al
    Collision diffuse large B cell lymphoma and myeloid sarcoma in the liver.
    Ann Hematol. 2021;100:2649-2651.
    PubMed    


    September 2021
  301. KIM TH, Choi YW, Ahn MS, Choi YS, et al
    Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia.
    Ann Hematol. 2021 Sep 30. pii: 10.1007/s00277-021-04673.
    PubMed     Abstract available


  302. ZHAO P, Ni M, Ma D, Fang Q, et al
    Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Sep 27. pii: 10.1007/s00277-021-04674.
    PubMed     Abstract available


  303. FAGUNDES EM, Neto NN, Caldas LM, Aragao JR, et al
    Mortality by COVID-19 in adults with acute myeloid leukemia: a survey with hematologists in Brazil.
    Ann Hematol. 2021 Sep 17. pii: 10.1007/s00277-021-04659.
    PubMed    


  304. XU RZ, Karsan A, Xu Z, Berry BR, et al
    A rare de novo pure erythroid leukemia with JAK2 R683S mutation.
    Ann Hematol. 2021 Sep 4. pii: 10.1007/s00277-021-04657.
    PubMed    


  305. YANADA M, Konuma T, Yamasaki S, Mizuno S, et al
    The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04661.
    PubMed     Abstract available


  306. FUJI S, Kida S, Nakata K, Morishima T, et al
    Long-term trends in the clinical outcomes of patients with acute myeloid leukemia: a population-based real-world data analysis using the Osaka Cancer Registry.
    Ann Hematol. 2021 Sep 3. pii: 10.1007/s00277-021-04631.
    PubMed     Abstract available


  307. HEINICKE T, Krahl R, Kahl C, Cross M, et al
    Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
    Ann Hematol. 2021;100:2387-2398.
    PubMed     Abstract available


  308. QI J, Zhang R, Cai C, Wang H, et al
    HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant.
    Ann Hematol. 2021;100:2351-2361.
    PubMed     Abstract available


  309. CHEN X, Liu C, Zhang A, Wu W, et al
    Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
    Ann Hematol. 2021;100:2269-2277.
    PubMed     Abstract available


  310. SIM JPY, Lie AKW, Ng MY, Kwong YL, et al
    Durable remission of T cell lymphoblastic lymphoma relapsing after allogeneic haematopoietic stem cell transplantation with a single low dose of nivolumab.
    Ann Hematol. 2021;100:2399-2402.
    PubMed    


    August 2021
  311. GUERY R, Suarez F, Lanternier F, Bougnoux ME, et al
    Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa.
    Ann Hematol. 2021 Aug 13. pii: 10.1007/s00277-021-04622.
    PubMed     Abstract available


  312. TACHIBANA T, Kanda J, Ishizaki T, Najima Y, et al
    Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
    Ann Hematol. 2021 Aug 6. pii: 10.1007/s00277-021-04607.
    PubMed     Abstract available


  313. MIAN AA, Haberbosch I, Khamaisie H, Agbarya A, et al
    Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K).
    Ann Hematol. 2021;100:2023-2029.
    PubMed     Abstract available


  314. WELLBROCK J, Behrmann L, Muschhammer J, Modemann F, et al
    The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia.
    Ann Hematol. 2021 Aug 1. pii: 10.1007/s00277-021-04602.
    PubMed     Abstract available


    July 2021
  315. MI R, Chen L, Yang H, Zhang Y, et al
    Combined use of interferon alpha-1b, interleukin-2, and thalidomide to reverse the AML1-ETO fusion gene in acute myeloid leukemia.
    Ann Hematol. 2021 Jul 27. pii: 10.1007/s00277-021-04621.
    PubMed     Abstract available


  316. MATSUDA K, Jo T, Toyama K, Nakazaki K, et al
    Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan.
    Ann Hematol. 2021 Jul 26. pii: 10.1007/s00277-021-04620.
    PubMed     Abstract available


  317. ALRAWASHDH N, Sweasy J, Erstad B, McBride A, et al
    Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04600.
    PubMed     Abstract available


  318. ELNAIR R, Ellithi M, Kallam A, Shostrom V, et al
    Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04603.
    PubMed     Abstract available


  319. KONG J, Qin YZ, Zhao XS, Hou Y, et al
    Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04606.
    PubMed     Abstract available


  320. MICHAELIS S, Pichler A, Stelzer I, Schoffmann L, et al
    Aggressive NK-cell leukemia with hemophagocytosis in a Caucasian patient.
    Ann Hematol. 2021 Jul 16. pii: 10.1007/s00277-021-04585.
    PubMed    


  321. HARA R, Onizuka M, Kikkawa E, Shiraiwa S, et al
    Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ann Hematol. 2021 Jul 11. pii: 10.1007/s00277-021-04587.
    PubMed     Abstract available


  322. BARZEGAR M, Farsani MA, Rafiee M, Amiri V, et al
    Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARalpha transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04579.
    PubMed     Abstract available


  323. TANIGAWA T, Sakurai M, Kato J, Mizuno K, et al
    Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2021 Jul 8. pii: 10.1007/s00277-021-04586.
    PubMed    


  324. GREIL R, Tedeschi A, Moreno C, Anz B, et al
    Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
    Ann Hematol. 2021;100:1733-1742.
    PubMed     Abstract available


  325. GADGEEL M, AlQanber B, Buck S, Taub JW, et al
    Aberrant myelomonocytic CD56 expression in Down syndrome is frequent and not associated with leukemogenesis.
    Ann Hematol. 2021;100:1695-1700.
    PubMed     Abstract available


    June 2021
  326. VIRK H, Rana S, Sharma P, Bose PL, et al
    Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
    Ann Hematol. 2021 Jun 22. pii: 10.1007/s00277-021-04574.
    PubMed     Abstract available


  327. WYSOCKA-SLOWIK A, Gil L, Slebioda Z, Kregielczak A, et al
    Oral mucositis in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation in relation to the conditioning used prior to transplantation.
    Ann Hematol. 2021 Jun 12. pii: 10.1007/s00277-021-04568.
    PubMed     Abstract available


  328. KRECAK I, Cengic M, Skoric I, Nakic M, et al
    Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Ann Hematol. 2021 Jun 10. pii: 10.1007/s00277-021-04570.
    PubMed    


  329. DOU X, Zheng F, Zhang L, Jin J, et al
    Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study.
    Ann Hematol. 2021 Jun 5. pii: 10.1007/s00277-021-04544.
    PubMed     Abstract available


  330. AL-SARAYFI D, Meeuwes FO, Munnink TO, Plattel W, et al
    Successful treatment of hairy cell leukemia variant with obinutuzumab.
    Ann Hematol. 2021 Jun 4. pii: 10.1007/s00277-021-04559.
    PubMed    


  331. LARIBI K, Sobh M, Ghez D, Baugier de Materre A, et al
    Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML: review.
    Ann Hematol. 2021;100:1359-1376.
    PubMed     Abstract available


  332. ZENG Z, Ly C, Daver N, Cortes J, et al
    High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
    Ann Hematol. 2021;100:1485-1496.
    PubMed     Abstract available


    May 2021
  333. HEUSER M, Smith BD, Fiedler W, Sekeres MA, et al
    Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Ann Hematol. 2021 May 12. pii: 10.1007/s00277-021-04545.
    PubMed    


  334. KONG J, Chen N, Li M, Zhang J, et al
    Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
    Ann Hematol. 2021 May 6. pii: 10.1007/s00277-021-04530.
    PubMed    


  335. DEVOS T, Havelange V, Theunissen K, Meers S, et al
    Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Ann Hematol. 2021 May 4. pii: 10.1007/s00277-021-04507.
    PubMed     Abstract available


  336. GONZALEZ JS, Perusini MA, Basquiera AL, Alfonso G, et al
    Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients.
    Ann Hematol. 2021 May 1. pii: 10.1007/s00277-021-04539.
    PubMed     Abstract available


  337. SALAMONOWICZ-BODZIOCH M, Fraczkiewicz J, Czyzewski K, Zajac-Spychala O, et al
    Prospective analysis of BKV hemorrhagic cystitis in children and adolescents undergoing hematopoietic cell transplantation.
    Ann Hematol. 2021;100:1283-1293.
    PubMed     Abstract available


  338. TANG KHK, Ip AHW, Kwong YL
    Clonal derivation of sequential seminoma and acute megakaryoblastic leukaemia.
    Ann Hematol. 2021;100:1337-1339.
    PubMed    


  339. HORIUCHI M, Yoshida M, Yamasaki K, Sakagami R, et al
    Effective treatment with imatinib for acute B-lymphoblastic leukaemia with EBF1-PDGFRB fusion.
    Ann Hematol. 2021;100:1329-1331.
    PubMed    


  340. BERNARDI S, Zanaglio C, Farina M, Polverelli N, et al
    dsDNA from extracellular vesicles (EVs) in adult AML.
    Ann Hematol. 2021;100:1355-1356.
    PubMed    


    April 2021
  341. MARTINEZ SANCHEZ MP, Megias-Vericat JE, Rodriguez-Veiga R, Vives S, et al
    A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
    Ann Hematol. 2021 Apr 29. pii: 10.1007/s00277-021-04542.
    PubMed     Abstract available


  342. ZHAO H, Sun J, Yan L, Jin B, et al
    Tissue factor-bearing microparticles are a link between acute promyelocytic leukemia cells and coagulation activation: a human subject study.
    Ann Hematol. 2021 Apr 24. pii: 10.1007/s00277-021-04533.
    PubMed     Abstract available


  343. KE P, Zhang X, Liu S, Zhu Q, et al
    The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen.
    Ann Hematol. 2021 Apr 22. pii: 10.1007/s00277-021-04528.
    PubMed     Abstract available


  344. ONAKA T, Kato-Ogura A, Otsuka Y, Iwai F, et al
    A case report of combined treatment of gilteritinib and LH-RH agonist for Fms-related tyrosine kinase 3 receptor mutation-positive acute myeloid leukemia and bone marrow metastasis of prostate cancer.
    Ann Hematol. 2021 Apr 12. pii: 10.1007/s00277-021-04516.
    PubMed    


  345. OWATTANAPANICH W, Herzig J, Jahn N, Panina E, et al
    Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Ann Hematol. 2021 Apr 10. pii: 10.1007/s00277-021-04513.
    PubMed     Abstract available


  346. QIAN Y, Chen Y, Li X
    CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* tetramutation co-contribute to myeloblast transformation in a chronic neutrophilic leukemia.
    Ann Hematol. 2021 Apr 6. pii: 10.1007/s00277-021-04491.
    PubMed     Abstract available


  347. RETTIG AR, Ihorst G, Bertz H, Lubbert M, et al
    Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis.
    Ann Hematol. 2021 Apr 1. pii: 10.1007/s00277-021-04494.
    PubMed     Abstract available


    January 2021
  348. LIU J, Shen L, Huang H, Gao X, et al
    A rare case of donor-derived promyelocytic sarcoma in a kidney transplant recipient.
    Ann Hematol. 2021;100:295-296.
    PubMed    


    June 2020
  349. HOCHMAN MJ, Martin DB
    Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL.
    Ann Hematol. 2020 Jun 16. pii: 10.1007/s00277-020-04091.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.